Correction: Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from second-line immunotherapy in NSCLC.

Ismail, R K; Schramel, F M N H; van Dartel, M; Pasmooij, A M G; der Welle, C M Cramer-van; Hilarius, D L; de Boer, A; Wouters, M W J M; van de Garde, E M W

Ismail, R K; Schramel, F M N H; van Dartel, M; Pasmooij, A M G; der Welle, C M Cramer-van; Hilarius, D L; de Boer, A; Wouters, M W J M; van de Garde, E M W.

Afiliación

Ismail RK; Dutch Institute for Clinical Auditing, Leiden, the Netherlands. r.ismail@dica.nl.
Schramel FMNH; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands. r.ismail@dica.nl.
van Dartel M; Medicines Evaluation Board, Utrecht, The Netherlands. r.ismail@dica.nl.
Pasmooij AMG; Department of Pulmonary Diseases, St Antonius Hospital, Nieuwegein, The Netherlands.
der Welle CMC; Medicines Evaluation Board, Utrecht, The Netherlands.
Hilarius DL; Medicines Evaluation Board, Utrecht, The Netherlands.
de Boer A; Santeon Hospital Group, Utrecht, The Netherlands.
Wouters MWJM; Department of Clinical Pharmacy, Rode Kruis Hospital, Beverwijk, The Netherlands.
van de Garde EMW; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands.

BMC Med Res Methodol ; 23(1): 26, 2023 Jan 27.

Article en En | MEDLINE | ID: mdl-36707787

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: BMC Med Res Methodol Asunto de la revista: MEDICINA Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google